8月13日主力资金净流出2934.93万元，近五日累计净流出9731.15万元。 风险提示：股市有风险，投资需谨慎。 海南海药8月13日股价报收6.20元，较前一交易日下跌1.27%。当日成交量为450581手，成交金额达2.79 亿元。 海南海药属于化学制药行业，主营业务涵盖药品研发、生产和销售。公司产品线包括抗生素、抗肿瘤 药、心血管药等多个治疗领域。 公司最新披露，目前正在进行氟非尼酮Ⅱ期临床数据分析工作。此外，公司有注射用头孢唑肟钠、罗沙 司他胶囊、地氯雷他定口服溶液三个药品被纳入国家医保局第十一批集采名单。 ...

Core Viewpoint - Hainan Haiyao Co., Ltd. is accelerating its transformation into an innovative R&D pharmaceutical manufacturer, focusing on the development of new drugs and leveraging the Hainan Free Trade Port policies to enhance its product pipeline and contribute to public health [2][3][4]. Group 1: Innovation and R&D - The company has made significant progress with two new drugs, Fluorofenidone and Paenangin, marking a shift towards innovative drug development [2]. - Hainan Haiyao is committed to developing strategic emerging industries, establishing platforms for large molecule CDMO and national-level testing, and expanding its pipeline for rare and prevalent diseases [2][4]. - The company has increased its R&D investment and has achieved notable success in the generic drug sector, with 34 specifications of 16 products passing consistency evaluations since 2021 [4]. Group 2: International Collaboration and Product Introduction - Hainan Haiyao is actively introducing high-quality foreign products to enrich its product pipeline and enhance medical service levels, establishing partnerships with international biopharmaceutical companies [3]. - The company is negotiating with several global pharmaceutical giants to select products with advanced technology and significant market potential for introduction into China [3]. Group 3: Talent Development and Research Infrastructure - Hainan Haiyao has recruited over 90 high-level R&D talents from prestigious universities both domestically and internationally, establishing a new drug R&D system that integrates production, learning, and research [3]. - The company has set up specialized teams for overseas product introduction and technical analysis to accelerate the integration of advanced biopharmaceutical products [3].